XBIO: xeneticbio.com Company Value to Net Income

Xenetic Biosciences, Inc. - graphic logo of issuer XBIO

The business model of Xenetic Biosciences (XBIO) is based on the efficacy of the DNase system in treating dense neoplasms, where success depends on test results and partner payments. This daily price chart on GURU.Markets, which carries the value -1.00, is supported by the work of top biopharmaceutical experts developing methods to combat resistant forms of cancer. Optimized reagent supply chains ensure a steady pace of scientific research.

Price to Earnings Ratio: Xenetic Bio (XBIO) for 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for Xenetic Biosciences Inc. (XBIO)

General company analysis:Xenetic Biosciences, Inc. XBIO
Flagship merchandise of Xenetic Biosciences, Inc.

Xenetic Biosciences (XBIO) is developing the DNase platform to optimize solid tumor therapies and secure contracts with pharmaceutical behemoths. By analyzing the issuer's P/E history, an investor assesses the market value of a single unit of net profit. This metric compares the current share price with actual earnings, identifying whether the business is overvalued or undervalued. The coefficient's trend reflects market confidence in the monetization of clinical successes, while a rising indicator signals priced-in expectations for future royalty payments.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ARTV: P/E Multiple|ANL: Market Price to Net Income Ratio|Price to Earnings Ratio VERU|TPST: Company Value to Net Income|Price to Earnings Ratio xiliotx.com (XLO)|Renovaro - Price to Earnings Multiple|Price to Earnings Ratio Mural Oncology MURA|KAPA - Price to Earnings Ratio|OKUR - Price to Earnings Ratio|GDTC - P/E Multiple|Curis, Inc. (CRIS) - Price to Earnings Ratio|Price to Earnings Ratio Apollomics, Inc.|Price to Earnings Ratio THAR|Price to Earnings Multiple ADVB (Advanced Biomed)|Price to Earnings Ratio GNPX (Genprex, Inc)|CLDI: Market Cap to Net Income|Price to Earnings Ratio sunshinebiopharma.com SBFM|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV